Monday, December 19, 2016

BRIEF-Loxo Oncology outlines plans for accelerated path to U.S.FDA approval for larotrectinib

* Loxo Oncology outlines plans for accelerated path to

U.S.FDA approval for larotrectinib (loxo-101) and provides

comprehensive pipeline update

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)